SCHEDULE: Affinity Asset Advisors Discloses iBio Stake

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 9.99% of iBio, Inc.'s common stock as of March 31, 2026.

Summary

• Affinity Asset Advisors, LLC and Michael Cho (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership of iBio, Inc. common stock.
• As of March 31, 2026, the Reporting Persons beneficially owned 3,489,048 shares of iBio, Inc. common stock.
• This ownership represents approximately 9.99% of the company's outstanding common stock.
• The reported shares include 381,848 shares issuable upon the exercise of warrants, subject to a 9.99% beneficial ownership limitation.
• Affinity Asset Advisors, LLC is the investment manager for Affinity Healthcare Fund, LP, which directly holds the securities.
• Michael Cho, as the managing member of Affinity Asset Advisors, LLC, may be deemed a beneficial owner of these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance data for iBio, Inc., making it difficult to assess the underlying company's health or future prospects based solely on this document.

Positives

• Affinity Asset Advisors, LLC and Michael Cho have disclosed a significant stake in iBio, Inc., indicating investor interest.
• The Reporting Persons hold sole voting and dispositive power over the reported shares, suggesting direct control over their investment decisions.
• The ownership level of 9.99% is close to the 10% threshold that often triggers more stringent reporting requirements, indicating a substantial investment.

Negatives

• The filing does not provide specific financial performance data for iBio, Inc., making it difficult to assess the company's current health.
• The beneficial ownership limitation of 9.99% on warrants suggests potential constraints on further increasing their stake without triggering additional reporting or regulatory scrutiny.

Risks

• The beneficial ownership limitation of 9.99% on warrants could restrict the Reporting Persons' ability to exercise all their warrants if it would cause them to exceed this ownership threshold.
• The filing does not detail specific risks related to iBio, Inc.'s business operations or market conditions, which are typically found in other SEC filings like 10-K or 10-Q.

Future Outlook

The filing is a Schedule 13G, which primarily reports ownership stakes and does not contain forward-looking statements or guidance from iBio, Inc. regarding its future financial performance or strategic plans.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders to report their holdings. This filing indicates that Affinity Asset Advisors, LLC and Michael Cho have taken a notable position in iBio, Inc., which operates in the biotechnology sector. Such filings can signal increased investor scrutiny or potential for future activism, depending on the investor's strategy.

Stakeholder Impact

• Shareholders: The filing indicates a significant investor's interest in iBio, Inc., which could influence market perception and potentially lead to future strategic actions by the investor.
• Management: The reporting persons' substantial stake may lead to increased engagement or scrutiny from iBio, Inc.'s management regarding company strategy and performance.

Next Steps

• Monitor future filings from Affinity Asset Advisors, LLC and Michael Cho for any changes in their ownership stake in iBio, Inc.
• Review iBio, Inc.'s subsequent financial reports (e.g., 10-Q, 10-K) for operational and financial performance updates.

Key Dates

Keywords

iBio, Inc., Schedule 13G, Affinity Asset Advisors, LLC, Michael Cho, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment Management